Shamburg News · 8-K filed Nov 9, 2026, 7:30 AM EST

Azora Therapeutics Adds Three Directors and Four Board Resignations Take Effect

AZR · Azora Therapeutics, Inc. (DE)

  • Leadership change
  • Shareholder vote
  • Other event
  • Materiality: medium

On November 3, 2026, Azora Therapeutics, Inc. (formerly Adial Pharmaceuticals, Inc.) appointed Aida Habtezion, M.D., Paul Hastings and Thomas Soloway to its Board of Directors and reconstituted its committees. J. Kermit Anderson, Cary J. Claiborne, Robertson H. Gilliland and Kevin Schuyler resigned from the Board effective the same date, and Matthew Davidson was appointed Board chair and the Board was reduced to five members. In a separate Item 8.01 disclosure, 9,924.260 shares of Series A Preferred Stock automatically converted into 9,924,260 shares of Common Stock effective November 2, 2026, leaving 14,243,129 common shares outstanding as of November 4, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 8.01, 9.01, accession 0001213900-26-117201.

Written from the filing by Shamburg Markets. Figures are as reported by the company.